Full Generic Medicine Info
Dosage/Direction for Use

Adult: Initially, 3-5 mg/kg daily in 2 or 3 divided doses. Maintenance: 3-8 mg/kg daily up to 10-15 mg/kg daily in patients w/ refractory hypoglycaemia or insulinoma.
Child: Neonates: Initially, 5 mg/kg bid. Maintenance: 1.5-3 mg/kg bid or tid up to 7 mg/kg tid may be required in some cases. ≥1 mth Initially, 1.7 mg/kg tid. Maintenance: 1.5-3 mg/kg bid or tid up to 5 mg/kg tid may be required in some cases.
Renal impairment: Dose reductions may be necessary.
Incompatibility: Incompatible w/ hydralazine HCl, lidocaine HCl and propranolol HCl.

Hypertensive crisis
Adult: 1-3 mg/kg w/in 30 seconds (max: 150 mg), repeated after 5-15 min if required.
Child: ≥1 mth Same as adult dose.
Renal impairment: Dose reductions may be necessary.
Incompatibility: Incompatible w/ hydralazine HCl, lidocaine HCl and propranolol HCl.
Management of functional hypoglycaemia.
Special Precautions
Patient in whom retention of Na and water may be hazardous (e.g. impaired cardiac or cerebral circulation); patient w/ aortic coarctation, arteriovenous shunt, heart failure or other cardiac disorders in which increase in cardiac output could be detrimental; hyperuricaemia or history of gout; patient w/ risk factors for pulmonary HTN. Renal impairment. Childn. Pregnancy and lactation. Monitoring Parameters Monitor BP, glucose levels, white cell and platelet count regularly in prolonged therapy. Regularly assess bone and psychological maturation and growth in childn. Monitor serum uric acid in uremic patients.
Adverse Reactions
Inappropriate hypotension and hyperglycaemia, including ketoacidosis and hyperosmolar nonketotic coma; oedema due to salt and water retention, precipitating heart failure; dysgeusia, nausea, anorexia and other GI disturbances, mild hyperuricaemia, extrapyramidal symptoms, eosinophilia and thrombocytopenia, dyspnoea, hypertrichosis, headache, dizziness, tinnitus, blurred vision; hypersensitivity, manifested as rashes, leucopenia and fever. IV: Coronary ischaemia leading to angina, cardiac arrhythmias, marked ECG changes, tachycardia, palpitations, bradycardia; cerebral ischaemia leading to confusion, convulsions, loss of consciousness and neurological deficit; impaired renal function, vasodilatation symptoms, burning sensation in the vein used for inj; pulmonary HTN in neonates and infants.
Symptoms: Marked hyperglycaemia associated w/ ketoacidosis, severe hypotension. Management: Promptly treat hyperglycaemia w/ insulin and restore fluid and electrolyte balance. If necessary, control hypotension w/ sympathomimetic agents.
Drug Interactions
Enhanced hyperglycaemic, hyperuricemic or hypotensive effects w/ diuretics. Increased risk of hypotension w/ other antihypertensive drugs or vasodilators. Increased risk of hyperglycaemia w/ concomitant phenytoin, corticosteroids or oestrogen-progestogen combinations. May displace other highly protein-bound drugs (e.g. coumarin and its derivatives) resulting in higher blood levels of these substances.
Lab Interference
False-negative insulin response to glucagon.
Diazoxide increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the β-cells of the pancreas, and may increase the hepatic output of glucose. When given IV, it produces a fall in BP by causing vasodilation of the arterioles, thus a reduction in peripheral resistance. It has an antidiuretic action and produces fluid and electrolyte retention.
Onset: Hyperglycaemic: W/in 1 hr (oral).
Duration: Hyperglycaemic: ≤8 hr (oral). Antihypertensive effect: 3-12 hr (IV).
Absorption: Readily absorbed from the GI tract.
Distribution: Crosses the placenta and blood-brain barrier. Plasma protein binding: >90%.
Metabolism: Partially metabolised in the liver via oxidation and sulphate conjugation.
Excretion: Via urine as unchanged drug (50%) and metabolites; faeces (small amounts). Plasma half-life: Approx 20-45 hr.
Intravenous: Inj soln: Store below 25°C. Protect from light. Avoid excessive heat and freezing. Oral: Oral susp: Store between 2-30°C. Protect from light, heat and freezing.
CIMS Class
Other Agents Affecting Metabolism / Other Antihypertensives
ATC Classification
V03AH01 - diazoxide ; Belongs to the class of drugs used in the treatment of hypoglycemia.
C02DA01 - diazoxide ; Belongs to the class of thiazide derivative agents acting on arteriolar smooth muscle. Used in the treatment of hypertension.
Disclaimer: This information is independently developed by CIMS based on diazoxide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in